| Patient | John Locke |
|---|---|
| Date of birth | 1632-09-08 |
| Identifiers | MRN HR-EN001-SYN-TD; SSN (made up) 000-01-8305 |
| Document date | 2026-11-01 |
| Author | Prudence Hartwell-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for a lifelong cough with wheeze and breathlessness, worse in city air and by open fires, in a never-smoker. Concerns: He has coughed for twenty years, and the city air leaves him unable to breathe; he wants to be able to do his work there; He wonders whether this is the consumption that his father and brother had; He asks whether the fire in his study is part of the problem. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry | Two puffs every 4 hours as needed | Respiratory tract route | 1692-03-12 to 1692-03-26 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | Two inhalations twice daily plus one as needed; no more than 12 a day | Respiratory tract route | 1692-03-26 | active | S |
| Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) | Two inhalations once a day | Respiratory tract route | 1692-06-18 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for aches or fever, no more than 3 g a day | One or two tablets every 6 hours as needed; no more than six tablets a day | Oral route | 1692-10-08 to 1692-10-22 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest X-ray, posteroanterior and lateral: mild hyperinflation; normal heart size; no consolidation, mass, cavitation, hilar enlargement, or effusion | 1692-03-12 to 1692-03-12 | completed | S |
| CT of the chest without contrast, with expiratory images: diffuse bronchial wall thickening and mosaic attenuation with air trapping on expiration; no emphysema, bronchiectasis, nodules, lymph node enlargement, or interstitial lung disease | 1692-03-26 to 1692-03-26 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1687-05-10 | Tdap vaccine | completed | S |
| 1691-10-14 | Influenza vaccine, last season | completed | S |
| 1692-03-26 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1692-09-17 | Influenza vaccine, 1692-1693 season | completed | S |
| 1692-09-17 | COVID-19 mRNA vaccine, this season's formula | completed | S |
| 1692-09-17 | Respiratory syncytial virus vaccine, single dose | completed | S |
| 1692-10-22 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| About 1670 | A cough that began about the age of 38 and troubled him thereafter, by his biographer's account | D (CLM-0006) |
| From 1679 | Unable to stay long in London because of its coal smoke, and away from the city every winter | D (CLM-0007) |
| 1691 to 1692 | Moved to the country because the smoke of London harmed his health; wrote that his lungs could not bear the smoke of the city | D (CLM-0010, CLM-0011) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died at about 54 of consumption or some kindred malady, by his biographer's account | D (CLM-0003) | |
| brother | Died of consumption at about 26, by his biographer's account | D (CLM-0003) |
| Concern | Status | Evidence |
|---|---|---|
| He has coughed for twenty years, and the city air leaves him unable to breathe; he wants to be able to do his work there | active | S |
| He wonders whether this is the consumption that his father and brother had | active | S |
| He asks whether the fire in his study is part of the problem | active | S |
Most recent measures: Total score [ACT] 21 on 1692-10-22; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1692-09-17; Hemoglobin [Mass/volume] in Blood 14.8 on 1692-03-12; Leukocytes [#/volume] in Blood by Automated count 7.4 on 1692-03-12; Eosinophils [#/volume] in Blood by Automated count 0.46 on 1692-03-12; Platelets [#/volume] in Blood by Automated count 251 on 1692-03-12; IgE [Units/volume] in Serum or Plasma 186 on 1692-03-12; Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma 131 on 1692-03-12; Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 58 on 1692-03-12; Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood 0.02 on 1692-03-12; FEV1 --pre bronchodilation 2.46 on 1692-06-18; Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation 3.71 on 1692-03-26; FEV1/FVC 0.57 on 1692-03-26; FEV1 measured/predicted 73 on 1692-06-18; FEV1 --post bronchodilation 2.58 on 1692-06-18; Forced vital capacity [Volume] Respiratory system --post bronchodilation 4.12 on 1692-06-18; FEV1/FVC --post bronchodilation 0.63 on 1692-06-18; Diffusion capacity.carbon monoxide 26.4 on 1692-03-26; Fractional concentration of exhaled nitric oxide 22 on 1692-06-18; Six minute walk test 505 on 1692-06-18; Cholesterol [Mass/volume] in Serum or Plasma 182 on 1692-09-17; Cholesterol in HDL [Mass/volume] in Serum or Plasma 64 on 1692-09-17; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 101 on 1692-09-17; Triglyceride [Mass/volume] in Serum or Plasma 85 on 1692-09-17; Maximum expiratory gas flow Respiratory system airway by Peak flow meter 430 on 1692-10-22 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluation | resolved | confirmed | R05.3 | S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit. |
| Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at home | active | confirmed | Z77.110 | S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted. |
| Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPD | active | confirmed | J45.40 | S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R). |
| Acute viral upper respiratory infection (common cold) with a yellow-zone asthma flare: peak flow 68 percent of personal best, managed with extra as-needed budesonide-formoterol by his action plan, without oral corticosteroids; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented autumn chest troubles (CLM-0014). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1692-03-12 | Total score [ACT] | 12 | {score} | S | ||
| 1692-03-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1692-03-12 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1692-03-12 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1692-03-12 | Eosinophils [#/volume] in Blood by Automated count | 0.46 | 10*3/uL | 0.15 or more suggests type 2 airway inflammation; 0.30 or more is typical of it | Normal | S |
| 1692-03-12 | Platelets [#/volume] in Blood by Automated count | 251 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1692-03-12 | IgE [Units/volume] in Serum or Plasma | 186 | [IU]/mL | <=100 [IU]/mL | High | S |
| 1692-03-12 | Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma | 131 | mg/dL | 90-200 mg/dL | Normal | S |
| 1692-03-12 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 58 | pg/mL | Below 125 pg/mL makes heart failure unlikely in an outpatient | Normal | S |
| 1692-03-12 | Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood | 0.02 | [IU]/mL | Positive at 0.35 IU/mL or more | Normal | S |
| 1692-03-26 | FEV1 --pre bronchodilation | 2.11 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 1692-03-26 | Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation | 3.71 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 L | Normal | S |
| 1692-03-26 | FEV1/FVC | 0.57 | {ratio} | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm | Low | S |
| 1692-03-26 | FEV1 measured/predicted | 62 | % | GLI Global race-neutral equations for a man of 59, 178 cm | Low | S |
| 1692-03-26 | FEV1 --post bronchodilation | 2.49 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 1692-03-26 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 4.02 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 L | Normal | S |
| 1692-03-26 | FEV1/FVC --post bronchodilation | 0.62 | {ratio} | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitation | Low | S |
| 1692-03-26 | Diffusion capacity.carbon monoxide | 26.4 | mL/min/mm[Hg] | Lower limit of normal, GLI 1683 race-neutral equations; predicted 26.9 | Normal | S |
| 1692-03-26 | Fractional concentration of exhaled nitric oxide | 41 | [ppb] | In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS) | High | S |
| 1692-03-26 | Six minute walk test | 430 | m | Predicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 m | Low | S |
| 1692-03-26 | Total score [ACT] | 13 | {score} | S | ||
| 1692-06-18 | Total score [ACT] | 19 | {score} | S | ||
| 1692-06-18 | FEV1 --pre bronchodilation | 2.46 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 1692-06-18 | FEV1 measured/predicted | 73 | % | GLI Global race-neutral equations for a man of 59, 178 cm | Low | S |
| 1692-06-18 | FEV1 --post bronchodilation | 2.58 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 1692-06-18 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 4.12 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 L | Normal | S |
| 1692-06-18 | FEV1/FVC --post bronchodilation | 0.63 | {ratio} | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitation | Low | S |
| 1692-06-18 | Fractional concentration of exhaled nitric oxide | 22 | [ppb] | In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS) | Normal | S |
| 1692-06-18 | Six minute walk test | 505 | m | Predicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 m | Normal | S |
| 1692-09-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1692-09-17 | Cholesterol [Mass/volume] in Serum or Plasma | 182 | mg/dL | <=199 mg/dL | Normal | S |
| 1692-09-17 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 64 | mg/dL | >=40 mg/dL | Normal | S |
| 1692-09-17 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 101 | mg/dL | <=129 mg/dL | Normal | S |
| 1692-09-17 | Triglyceride [Mass/volume] in Serum or Plasma | 85 | mg/dL | <=149 mg/dL | Normal | S |
| 1692-10-08 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 300 | L/min | 80 percent of his personal best of 440 L/min | Low | S |
| 1692-10-22 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 430 | L/min | 80 percent of his personal best of 440 L/min | Normal | S |
| 1692-10-22 | Total score [ACT] | 21 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1692-03-12 | Body height | 178 | cm | S |
| 1692-03-12 | Body weight | 62 | kg | S |
| 1692-03-12 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 1692-03-12 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1692-03-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1692-03-12 | Heart rate | 84 | /min | S |
| 1692-03-12 | Respiratory rate | 18 | /min | S |
| 1692-03-12 | Body temperature | 36.6 | Cel | S |
| 1692-03-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1692-03-26 | Body height | 178 | cm | S |
| 1692-03-26 | Body weight | 62.1 | kg | S |
| 1692-03-26 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 1692-03-26 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1692-03-26 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1692-03-26 | Heart rate | 82 | /min | S |
| 1692-03-26 | Respiratory rate | 18 | /min | S |
| 1692-03-26 | Body temperature | 36.5 | Cel | S |
| 1692-03-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1692-06-18 | Body height | 178 | cm | S |
| 1692-06-18 | Body weight | 62.8 | kg | S |
| 1692-06-18 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1692-06-18 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1692-06-18 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1692-06-18 | Heart rate | 76 | /min | S |
| 1692-06-18 | Respiratory rate | 16 | /min | S |
| 1692-06-18 | Body temperature | 36.6 | Cel | S |
| 1692-06-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1692-09-17 | Body height | 178 | cm | S |
| 1692-09-17 | Body weight | 63 | kg | S |
| 1692-09-17 | Body mass index (BMI) [Ratio] | 19.9 | kg/m2 | S |
| 1692-09-17 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1692-09-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1692-09-17 | Heart rate | 74 | /min | S |
| 1692-09-17 | Respiratory rate | 16 | /min | S |
| 1692-09-17 | Body temperature | 36.6 | Cel | S |
| 1692-09-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1692-10-08 | Body height | 178 | cm | S |
| 1692-10-08 | Body weight | 62.6 | kg | S |
| 1692-10-08 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1692-10-08 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1692-10-08 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1692-10-08 | Heart rate | 94 | /min | S |
| 1692-10-08 | Respiratory rate | 20 | /min | S |
| 1692-10-08 | Body temperature | 37.6 | Cel | S |
| 1692-10-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1692-10-22 | Body height | 178 | cm | S |
| 1692-10-22 | Body weight | 62.8 | kg | S |
| 1692-10-22 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1692-10-22 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1692-10-22 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1692-10-22 | Heart rate | 74 | /min | S |
| 1692-10-22 | Respiratory rate | 16 | /min | S |
| 1692-10-22 | Body temperature | 36.5 | Cel | S |
| 1692-10-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1692-03-12 | Primary care visit for a lifelong cough with wheeze and breathlessness, worse in city air and by open fires, in a never-smoker | finished | S |
| 1692-03-26 | Two-week review of lung function and blood tests, diagnosis, start of treatment, and pulmonology consultation | finished | S |
| 1692-06-18 | Twelve-week asthma review with repeat spirometry after pulmonary rehabilitation | finished | S |
| 1692-10-22 | Asthma review two weeks after a cold with a yellow-zone flare | finished | S |
| 1692-09-17 | Preventive health visit at 60 | finished | S |
| 1692-10-08 | Same-day sick visit for a cold with a yellow-zone asthma flare | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Diagnostic workup: spirometry before and after bronchodilator, FeNO, DLCO, blood count with eosinophils, total IgE, alpha-1 antitrypsin, NT-proBNP, interferon-gamma release assay, chest X-ray, and CT of the chest if airflow limitation persists after bronchodilator; albuterol withheld for 6 hours before testing | completed | GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020, GL-GOLD-2025, GL-ATS-ERS-PFT-2022, GL-ATS-RACE-2023 | S |
| Exposure reduction from today: no open coal or wood fires in his rooms (electric or heat-pump heating instead); a portable HEPA air cleaner sized for his study and bedroom; daily check of the air quality index, with city trips and outdoor exertion avoided on alert days; a well-fitted N95 respirator on unavoidable high-pollution days; quieter routes away from main roads | completed | GL-WHO-AQG-2021, GL-ERS-AIR-2020, GL-AIRNOW-AQI, GL-EPA-AIRCLEAN, GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020 | S |
| Pulmonology consultation on the diagnosis (asthma, COPD, or both), the need for CT, treatment, and pulmonary rehabilitation | completed | GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020, GL-GOLD-2025 | S |
| Shared decision on treatment: budesonide-formoterol 160/4.5 mcg as maintenance and reliever, two inhalations twice daily plus one as needed, no more than 12 a day; albuterol stopped; inhaler technique taught and checked at every visit; a written asthma action plan | completed | GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020 | S |
| Pulmonary rehabilitation: an eight-week, twice-weekly program of supervised exercise training and education, with a six-minute walk test before and after | completed | GL-GINA-2025, GL-CMID-2026, GL-ATS-PR-2023 | S |
| Vaccinations: pneumococcal conjugate vaccine PCV20 at the diagnosis visit; influenza, COVID-19, and RSV vaccines in the autumn; recombinant zoster vaccine | completed | GL-CDC-IMZ-2026, GL-CMID-2026 | S |
| Monitoring: Asthma Control Test, inhaler technique, adherence, reliever use, and exposures at every visit; spirometry and FeNO 3 months after starting treatment, then every 1 to 2 years; home peak flow diary | completed | GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020 | S |
| Add-on tiotropium 2.5 mcg soft-mist inhaler, two inhalations once daily, for persistent symptoms and airflow limitation on medium-dose budesonide-formoterol; written action plan updated with peak-flow zones from his personal best of 440 L/min | completed | GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020 | S |
| After any flare: a review within one week, booked by the clinic when he calls or is seen for the flare | completed | GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Cause of the cough and breathlessness established by the second visit | 1692-03-26 | completed | Asthma with persistent airflow limitation confirmed by spirometry, FeNO, eosinophils, DLCO, and CT; tuberculosis, alpha-1 antitrypsin deficiency, and heart failure excluded | S |
| Asthma well controlled (Asthma Control Test 20 or more) with no flare needing oral corticosteroids | 1693-03-31 | active | ACT 21 at the last visit; one yellow-zone flare with a cold, managed by the action plan without oral corticosteroids | S |
| No indoor solid-fuel smoke and less outdoor pollution exposure | 1693-03-31 | active | Open fires out of use since intake; HEPA air cleaner in his study and bedroom; air quality alerts followed | S |
| Six-minute walk distance improved by at least 30 m after pulmonary rehabilitation | 1692-06-18 | completed | 430 m before and 505 m after an eight-week program | S |